AstraZeneca boosts China presence with FibroGen’s anemia drug in $160 million deal
(Reuters) -AstraZeneca will buy longtime partner FibroGen’s China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world’s second-biggest economy. The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, AstraZeneca’s biggest international…